Starling Oncology, Inc.
DFPH- Exchange
- OTC
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- SEC CIK
- 0001799191
In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Starling Oncology, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 53 | 50 | −3 |
| Shares | 21.6M | 21.8M | +221.0K (+1.0%) |
| Value | $214.7M | $216.7M | +$1.97M (+0.9%) |
New holders (5)
Institutions that held Starling Oncology, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 1,467,184 | $14.6M | 0.02% |
| Falcon Edge Capital, LP | 117,450 | $1.17M | 0.09% |
| Schonfeld Strategic Advisors LLC | 76,174 | $757.0K | 0.01% |
| Penserra Capital Management LLC | 3,955 | $39.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 452 | $4.00K | 0.00% |
Sold out (8)
Institutions that held Starling Oncology, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Park West Asset Management LLC | 1,255,063 | $12.5M |
| Kent Lake Capital LLC | 1,053,300 | $10.5M |
| Brant Point Investment Management LLC | 256,863 | $2.56M |
| Marshall Wace, LLP | 251,039 | $2.50M |
| Sphera Funds Management Ltd. | 126,491 | $1.26M |
| Sage Rock Capital Management LP | 105,691 | $1.05M |
| Aristeia Capital LLC | 62,500 | $622.0K |
| Morgan Stanley | 20,098 | $200.0K |